OKYO PHARMA LTD Stock Price, News & Analysis

OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) announced a purchase of 10,000 American Depositary Shares (ADSs) at $1.40 each by Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone. This transaction, valued at $14,000, is significant in the context of OKYO's development of OK-101, a treatment for dry eye disease in a burgeoning market. The purchase reflects confidence in OKYO’s strategy amidst the pressing need for innovative solutions in ophthalmology. The transaction took place on March 23, 2023, on the NASDAQ.

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company, announced the posting of its planned clinical trial for OK-101 to treat dry eye disease (DED) on ClinicalTrials.gov (Identifier: NCT05759208). The company is activating clinical sites and preparing the trial drug for shipment, anticipating the first-patient visit in early Q2 2023, with top-line data expected in Q4 2023. CEO Gary S. Jacob expressed optimism about OK-101 providing a new treatment option for DED patients who lack effective therapies.

OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) has announced a global private placement to raise approximately $5.4 million through the issuance of new American Depositary Shares (ADSs) and ordinary shares. The company will issue 3,503,665 new ADSs at $1.50 each, representing 227,738,225 ordinary shares, and 8,673,658 ordinary shares at $0.23 each. Proceeds will be utilized for advancing the Phase 2 clinical trial of OK-101 for dry eye disease (DED) and other corporate purposes. The closing of the U.S. Offering is expected on March 14, 2023, with shares expected to be listed on the London Stock Exchange shortly thereafter.

On March 13, 2023, OKYO Pharma announced a public offering of 3,503,665 American Depositary Shares (ADSs) at $1.50 each, aiming to raise approximately $5.3 million. The offering is set to close on March 15, 2023. The funds will primarily support the Phase 2 clinical trial of OK-101 for inflammatory dry eye diseases and will also cover general corporate expenses. Additionally, the company completed a concurrent offering in the UK, securing $0.3 million from the sale of 13,836,156 ordinary shares to management and directors. The registration statement for the ADSs was filed with the SEC and became effective on March 8, 2023.

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced that its GMP packaged drug OK-101 for treating dry eye disease (DED) has cleared customs in the U.S. The company is preparing for its first-in-human Phase 2 clinical trial, with randomization codes being generated and clinical sites being authorized. Anticipated timelines include the first patient visit in Q1 2023 and top-line data release in Q4 2023. OK-101 aims to address significant unmet needs in the multi-billion-dollar DED market, leveraging its unique design to enhance drug retention in the ocular environment.

OKYO Pharma has appointed Dr. Jay S. Pepose, a leading ophthalmologist, to its Scientific Advisory Board to guide clinical programs for OK-101, a treatment for dry eye disease. Dr. Pepose brings nearly 40 years of experience and a robust background in clinical trials for ophthalmic conditions. The company plans to initiate enrollment for its Phase 2 clinical trial for OK-101 within Q1 2023. This strategic appointment aims to enhance the profile of OK-101 amidst a multi-billion-dollar market with significant unmet needs. Dr. Pepose's insights on ocular inflammation and pain management are expected to drive the development of this promising therapy.

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced that CEO Gary S. Jacob, Ph.D., will present on the therapeutic potential of OK-101 for dry eye disease at the GPCRs-Targeted Drug Discovery Summit on February 22, 2023, in Boston. His presentation follows that of Dr. Alan Kopin, who will share insights on the discovery and testing of OK-101. Recently, OKYO received FDA clearance for its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial for OK-101, aiming to address the significant unmet need in treating dry eye disease.

OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO) has announced its interim results for the six months ending September 30, 2022. The company has achieved FDA IND clearance for its Phase 2 trial of OK-101 to treat Dry Eye Disease (DED), expected to begin in Q1 2023. Financially, OKYO reported total assets of £1.6 million and cash of £0.6 million, with a comprehensive loss of £4.6 million. The company has halted further development of OK-201 to focus resources on OK-101.

OKYO Pharma Limited has received FDA clearance to start a Phase 2 clinical trial for OK-101, a treatment for Dry Eye Disease (DED). This first-in-human study will assess both efficacy endpoints relating to the signs and symptoms of DED. The trial is set to begin in Q1 2023, aiming to demonstrate OK-101's potential as a novel treatment option for patients inadequately addressed by existing medications. The company emphasizes that success in this trial could expedite the filing for a new drug application (NDA) with the FDA.